JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Status:
RECRUITING
Trial end date:
2028-02-08
Target enrollment:
Participant gender:
Summary
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design.
Cohort A: Participants will be randomized to receive either a placebo or vilobelimab.
This record describes the default procedures and analyses for Cohort A. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.
Phase:
PHASE2
Details
Lead Sponsor:
PPD Development, LP
Collaborators:
Biomedical Advanced Research and Development Authority Edesa Biotech Inc. Genentech, Inc. InflaRx GmbH